Flexor10 mg

Flexor is a centrally-acting skeletal muscle relaxant, structurally related to the tricyclic antidepressants. Its established use is:

• FDA-approved indication: As an adjunct to rest and physical therapy for the short-term relief of muscle spasm associated with acute, painful musculoskeletal conditions (e.g. low back strain, neck strain, other soft-tissue injuries).

Flexor is not indicated for the treatment of spasticity associated with chronic neurological conditions such as cerebral palsy or spinal cord disease, and it does not directly relax skeletal muscle at the tissue level — its benefit comes from central nervous system effects that reduce muscle hyperactivity and associated pain, allowing more effective rest and physical therapy.

It is intended for short-term use only, typically not exceeding 2-3 weeks, as evidence of effectiveness beyond this period is limited.

Each tablet/capsule contains Cyclobenzaprine Hydrochloride as the active pharmaceutical ingredient, commonly available in 5 mg and 10 mg immediate-release tablet strengths, and in extended-release capsule formulations (e.g. 15 mg, 30 mg) in some markets. Formulations may also contain standard pharmaceutical excipients such as lactose, microcrystalline cellulose, magnesium stearate, and film-coating agents.

Flexor is a centrally-acting muscle relaxant that is chemically and pharmacologically related to the tricyclic antidepressants (it shares a very similar three-ring chemical structure with amitriptyline). It is used for the short-term symptomatic relief of muscle spasm caused by acute musculoskeletal injury, working together with rest and physical therapy rather than as a standalone treatment.

Unlike peripherally-acting agents, Flexor does not act directly at the neuromuscular junction or on muscle fibers; instead, it reduces motor activity primarily through effects within the brainstem.

Flexor belongs to the therapeutic class of centrally-acting skeletal muscle relaxants, a drug class structurally and pharmacologically related to the tricyclic antidepressants.

Mechanism of Action

Cyclobenzaprine Hydrochloride reduces muscle hyperactivity through action within the central nervous system, primarily at the level of the brainstem, rather than at the neuromuscular junction or muscle itself. It is believed to reduce tonic somatic motor activity, influencing both gamma and alpha motor neuron systems, without directly affecting neuromuscular transmission or muscle contractility.

Its molecular structure is closely related to tricyclic antidepressants, and it shares significant anticholinergic (antimuscarinic) activity, which accounts for common side effects such as dry mouth and blurred vision.

Pharmacokinetics

Cyclobenzaprine Hydrochloride is well absorbed orally, extensively bound to plasma proteins (~93%), metabolized in the liver via glucuronidation and CYP450 pathways (notably CYP3A4, CYP1A2), and has a long elimination half-life (approximately 18 hours, range 8-37 hours), consistent with its once-established slow onset and need for consistent dosing.

Flexor tablets can be taken with or without food, at consistent times each day. Extended-release capsules must be swallowed whole with water and should not be crushed, split, or chewed, as this could alter the release of medication and increase the risk of side effects.

The following interactions with Flexor are clinically significant:

• Monoamine oxidase inhibitors (MAOIs): Concurrent use, or use within 14 days of discontinuing an MAOI, is contraindicated due to risk of hyperpyretic crisis, seizures, and death (see Contraindications).
• CNS depressants (alcohol, benzodiazepines, opioids, barbiturates, sedatives): Additive sedative effects; concurrent use increases risk of drowsiness and impaired coordination and should be avoided or closely monitored.
• Tramadol: Additive effect on seizure threshold reduction; increased seizure risk with concurrent use.
• Anticholinergic drugs (e.g. antihistamines, antispasmodics, other tricyclics): Additive anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision).
• Guanethidine and related antihypertensives: Flexor may block the antihypertensive action of guanethidine-type agents due to its tricyclic-like structure.
• Serotonergic drugs (SSRIs, SNRIs, triptans): Theoretical additive risk of serotonin-related effects due to structural similarity to tricyclic antidepressants; use with caution.

The most common adverse effects associated with Flexor include:

• Drowsiness/somnolence (very common)
• Dry mouth (very common)
• Dizziness
• Fatigue
• Headache
• Blurred vision
• Constipation, dyspepsia, nausea
• Nervousness or confusion (more common in elderly)

Less common but more serious effects include tachycardia, palpitations, urinary retention, and (rarely) allergic reactions. Anticholinergic effects should be used with caution in patients with narrow-angle glaucoma or urinary retention/benign prostatic hyperplasia (see Precautions).

Pregnancy: Adequate and well-controlled studies in pregnant women are not available. Flexor should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Consult a physician before use if pregnant or planning pregnancy.

Lactation: It is not known whether Flexor is excreted in human breast milk. Because of the potential for sedation and anticholinergic effects in a nursing infant, caution should be exercised and a physician consulted before use while breastfeeding.

• Duration of use: Not recommended for use longer than 2-3 weeks; evidence of effectiveness for more prolonged treatment is limited.
• Sedation: Flexor commonly causes drowsiness; patients should be cautioned against driving, operating machinery, or performing hazardous tasks until they know how it affects them, and should avoid alcohol and other CNS depressants.
• Anticholinergic effects: Use with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, or benign prostatic hyperplasia.
• Elderly patients: Increased sensitivity to sedative and anticholinergic effects; use the lowest effective dose (see Use in Special Populations).
• Serotonin syndrome risk: Due to structural similarity to tricyclic antidepressants, caution is needed with concomitant serotonergic drugs.
• Hepatic impairment: Use with caution in mild impairment and avoid in moderate-to-severe hepatic impairment.
• Not indicated for the treatment of spasticity related to chronic neurological conditions such as cerebral palsy or spinal cord injury.

Overdose of Flexor may cause serious cardiac and central nervous system toxicity, similar to tricyclic antidepressant overdose, including severe drowsiness, agitation, hallucinations, tachycardia, cardiac arrhythmias, seizures, and (rarely) coma or death.

If overdose is suspected, seek immediate emergency medical attention or contact a poison control center right away. Hospital-based cardiac monitoring (ECG) is required. Do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and effectiveness of Flexor have not been established in patients younger than 15 years of age; it is not recommended for use in this population.

Elderly

Elderly patients are more sensitive to the sedative and anticholinergic effects of Flexor. Treatment should be initiated at the lowest dose (5 mg) with slow titration, and patients should be monitored closely.

Hepatic Impairment

Use with caution and at the lowest dose in patients with mild hepatic impairment; use is generally not recommended in moderate-to-severe hepatic impairment due to reduced clearance.

Renal Impairment

Specific dose adjustment data are limited; use with caution and clinical monitoring.

Treatment with Flexor should generally be limited to short-term use of 2-3 weeks, as this is the period over which clinical efficacy for acute muscle spasm has been demonstrated in controlled trials. Continued or recurrent need beyond this period should prompt physician reassessment.

Cyclobenzaprine Hydrochloride is classified as a centrally-acting skeletal muscle relaxant, structurally related to the tricyclic antidepressant class of drugs.

Cyclobenzaprine Hydrochloride acts primarily within the central nervous system (brainstem) to reduce tonic somatic muscle motor activity, rather than acting directly on skeletal muscle fibers or at the neuromuscular junction. This central action reduces muscle spasm and associated pain, facilitating rest and physical therapy.

B

Flexor is not recommended for use in patients younger than 15 years of age, as safety and effectiveness in this population have not been established.